Our evaluation of CDK9 expression in clinical prostate tissues supports this concept in a prostate cancer context: more specifically, we found that CDK9 expression is associated with tumor grade and is predictive of disease recurrence following surgery. The gene discussed is CDK9; the disease is prostate carcinoma.